The role of SGLT2 inhibitors beyond glucose-lowering to cardio-renal protection
People with type 2 diabetes mellitus (T2DM) are at high risk of developing cardiovascular disease (CVD) and kidney disease. This enhanced cardio-renal risk persists despite improvements in care and treatments over the last 20 years. Intensive glucose control alone does not substantially reduce the r...
Saved in:
| Main Author: | J. Karalliedde |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2021-04-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/4323 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Associations between intercurrent events and cardiorenal clinical outcomes in non-diabetic chronic kidney disease: a real-world retrospective cohort study in the United States
by: Christoph Wanner, et al.
Published: (2025-04-01) -
The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection
by: Emily Brown, et al.
Published: (2021-01-01) -
Cardiovascular Disease Assessment Prior to Kidney Transplantation
by: Angelina R. Edwards, et al.
Published: (2022-09-01) -
Risk factors and transitional probability of clinical events in Korean CKD patients using the multistate model
by: Ji Hye Kim, et al.
Published: (2025-03-01) -
Aging is associated with slower renal progression in patients with chronic kidney disease
by: Chia-Tse Yeh, et al.
Published: (2022-01-01)